This week, we have conversations with LinusBio founder and Mt. Sinai environmental professor, Dr. Manish Arora, as well as with Philippe Chambon, CEO of Cyllene Therapeutics (Cyllene Tx).
Times:
01:33 Cyllene Tx
21:37 LinusBio
Cyllene Therapeutics
Cyllene Therapeutics is a global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. It is currently executing a phase 1/2 study in the US with its lead DNA medicine candidate, EG110A, in patients with neurogenic detrusor overactivity (neurogenic bladder)-related incontinence.
This is the first human study with nrHSV vectors targeting sensory neuron-based diseases. EG110A is being developed to address multiple severe bladder diseases, including overactive bladder (OAB), and has the potential to be a major improvement over existing therapies, resulting in better care for patients and lower costs for healthcare systems.
The company’s HERMES platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Its vectors can achieve focal transduction and then selective expression of transgenes in targeted subsets of neurons. With demonstrated clinical safety and possible repeat dosing, the large payload capacity of nrHSV-1 vectors allows for versatile DNA delivery and smarter DNA medicine.
LinusBio
LinusBio’s Traced, which launched this month, is the first direct-to-consumer wellness test that uses a single strand of hair to provide a day-by-day view of exposure to 15 elements—including nutrients like zinc and magnesium, as well as toxic elements such as lead, arsenic, cadmium, and aluminium—over the course of 30 days.
Traced uses LinusBio’s proprietary platform, combining advanced robotics, laser ablation, and mass spectrometry to identify exposure patterns over time. Traced provides consumers with a 30-day history of all measured exposures. Levels are measured relative to LinusBio’s proprietary global reference database. It is not a measure of health or a diagnosis of any condition; it’s meant to inform consumers and empower them to take steps to mitigate their exposure.
Developed from research at Mount Sinai, Traced offers a different approach than traditional blood or urine testing by showing how exposures change over time and helping consumers connect those patterns to their daily routines, travel, homes, and environments.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com